Akash Verma

About Akash Verma

Driving Growth, Impact, and InnovationDivision Head at Dr. Reddy’s Laboratories with over 18 years of leadership across acute, chronic, and super specialty therapy segments, managing end-to-end responsibilities in sales, marketing, P&L, team building, and brand acceleration. Currently steering the Ortho Business Unit comprising Opera and Osteozen divisions with a team of 214 professionals and annual revenue of ₹135 Cr.Strategic Areas of Expertise:• P&L Management• Strategic Brand Planning & Portfolio Building• New Product Launch & Product Lifecycle Management• Megabrand Acceleration & Demand Planning• KOL Engagement & Key Account Management• Sales Process Excellence & Cross-Functional Collaboration• Talent Retention, Capability Building & Coaching• Patient Support Programs & Omnichannel MarketingPerformance that speaks:Successfully launched Amgen’s Romosozumab (Evenity), delivering ₹10 Cr in Year-1 and positioning Osteozen as the Best Division in FY25, including top honors in ASTRA process parameters. Turned around performance for Opera through optimized Nutra and pain portfolios, leading to 100%+ achievement in FY25. Directed multi-brand strategies across megabrands like Doxt-SL, Cetzine, Betonin, Lobate GM, and Paraxin, with repeat recognitions for turnaround success and brand sustainability in intensely competitive markets.Versatility across business models, therapy areas and geographies:Led regional and international portfolios spanning India, West Africa, and Southern Africa with marketing responsibility for $65Mn+ business across multiple therapy areas and consumer healthcare brands. Proven ability to adapt strategies for diverse market dynamics—whether launching biosimilars like Reditux, scaling chronic disease brands like Metsmall, or driving omnichannel initiatives across geographies and stakeholder networks. Worked across therapy areas - Oncology, Cardio-Diabetes, Acute (Mass segment, Derma, Gyne, Respiratory) & now Ortho. Have the experience of handling global Innovative assets like Prolia (Denosumab) & Evenity (Romosozumab) as a part of Amgen Osteoporosis portfolio marketing collaboration of Dr Reddy\'s. Accolades for Current BU Head role:Best Division Award - FY25 India Business HeadBest Division in Process (ASTRA)- FY25Best Division of Acute-1 Vertical FY23A leadership mindset built on purpose:Believes in leading through clarity, process, and purpose—growing brands by empowering teams, aligning metrics with mission, and focusing on outcomes that matter.

Experience

1. Division Head - Ortho Bus (Opera & Osteozen)

   Dr. Reddy's Laboratories

   Oct 2022 — Present · Hyderabad, IN

   Leading the Ortho business for Opera and Osteozen divisions with a combined field force of 200+, overseeing portfolios in pain management, nutraceuticals, and in-licensed innovator assets- Achieved 100%+ target for FY25 with robust execution across both divisions- Successfully launched Amgen global asset - Evenity (Romosozumab), clocking ₹10 Cr in Year1- Drove turnaround in Opera’s performance through focused execution in pain (Retoz & Ace Proxyvon) and Nutra portfolios (Cartilox & T-R3)- Steered the launch of T-R3 in the Nutra segment in Opera division- Positioned Osteozen as the best-performing super-specialty division of FY25 with top ASTRA process metrics in the year- Managed in-licensed brands Prolia, Evenity, and Durolane, expanding therapy leadershipOrtho Business Management, Pain Management, Nutraceutical Portfolio, In-Licensed Brands, Brand Launch, Division Leadership, Sales Force Management, Therapy Excellence

Education

• SVKM's Narsee Monjee Institute of Management Studies (NMIMS)

  Post Graduate Diploma in Pharmaceutical Management, Pharmaceutical Marketing and Management

  2005 — 2007